NewAmsterdam Pharma (NAMS) Intangibles (2022 - 2023)
NewAmsterdam Pharma (NAMS) posted Intangibles of $88.9 million for Q2 2023, up 4.77% sequentially from $84.8 million in Q4 2022.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Intangibles (2022 - 2023) Analysis & Trends
NewAmsterdam Pharma has reported Intangibles for 2 years, with the latest figure at $88.9 million in Q2 2023.
- Quarterly Intangibles changed N/A year-over-year to $88.9 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $88.9 million (changed N/A YoY) and the FY2022 annual result came in at $84.8 million, changed N/A from the prior year.
- Intangibles climbed to $88.9 million in Q2 2023 per NAMS's latest filing, from $84.8 million in the prior quarter.
- Over five years, Intangibles peaked at $88.9 million in Q2 2023 and troughed at $84.8 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 63.28 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 60.96 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | - |